Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Common Equity (2016 - 2025)

Anaptysbio (ANAB) has disclosed Common Equity for 10 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 47.49% year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Dec 2025, down 47.49%, and an annual FY2025 reading of $37.2 million, down 47.49% over the prior year.
  • Common Equity was $37.2 million for Q4 2025 at Anaptysbio, up from -$29.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $385.7 million in Q2 2021 and bottomed at -$44.7 million in Q2 2025.
  • Average Common Equity over 5 years is $172.0 million, with a median of $134.4 million recorded in 2023.
  • The sharpest move saw Common Equity increased 6.49% in 2021, then tumbled 552.81% in 2025.
  • Year by year, Common Equity stood at $356.4 million in 2021, then decreased by 26.46% to $262.1 million in 2022, then tumbled by 66.39% to $88.1 million in 2023, then dropped by 19.56% to $70.9 million in 2024, then plummeted by 47.49% to $37.2 million in 2025.
  • Business Quant data shows Common Equity for ANAB at $37.2 million in Q4 2025, -$29.4 million in Q3 2025, and -$44.7 million in Q2 2025.